Prescribing information

Introduction to GEP-NETs

While neuroendocrine tumours (NETs) can appear in most organs,1 the gastrointestinal system, including the pancreas, is the most common primary location of NETs.2 These tumours, described as gastroenteropancreatic neuroendocrine tumours (GEP-NETs), are commonly considered as slow-growing malignancies; however, some NETs are associated with rapid progression and poor prognosis.1 Symptoms are often non-specific and subtle,3,4 often leading to significant delays in diagnosis and a poor quality of life in these patients.4

Click on the following resources below and find out more information about GEP-NETs—their incidence, clinical behaviour and how they are diagnosed and treated.

1. Oronsky B, et al. Neoplasia. 2017;19(12):991–1002.
2. Dasari A, et al. JAMA Oncol. 2017;3:1335–42.
3. Boudreaux JP, et al. Pancreas. 2010;39:753–66.
4. Singh S, et al. J Glob Oncol. 2016;3:43–53.
AAA-Lu177-UK-2146 | October 2023

Ask Speakers


Medical Information Request